Clinical Trial Intelligence & Market Landscape for an Oncology Research Organisation
The oncology clinical trial landscape is enormous and moves fast. Understanding where the real white-space is – not just what's crowded – requires structured intelligence across hundreds of active and completed protocols. That's what GreyRadius delivered.
The Situation
A research pipeline to prioritise. A trial landscape too large to map without structured intelligence.
An oncology research organisation with a track record of commercially successful investigator-initiated and industry-sponsored trials needed to prioritise its next cycle of research investments. The leadership team had identified several promising therapeutic areas and patient populations – but the clinical trial landscape across these areas was dense, rapidly evolving, and difficult to assess without a systematic protocol analysis.
The risk of investing in a trial that duplicated existing or near-complete work was real – and the cost of that error, in funding, time, and researcher capacity, was significant. The organisation needed structured intelligence that went beyond a standard literature review: a competitive landscape analysis of active and recently completed trials that identified genuine white-space.
GreyRadius was engaged to map the oncology trial landscape across 12 sub-segments – analysing protocol designs, endpoints, sponsor profiles, trial status, and unmet need gaps – to identify where new research investment had the highest potential for differentiation and funding.
Engagement at a glance
Client
Oncology clinical research organisation
Service
Opportunity Assessment · AI Consulting
Scope
12 oncology sub-segments; 200+ trial protocols
Output
White-space map, 3 opportunities, 2 trial research briefs
In a landscape with thousands of active trials, finding real white-space requires systematic analysis, not instinct.
Landscape density and pace
The global oncology trial landscape adds hundreds of new protocols every quarter. Keeping track of what is active, what has completed, what has failed, and where the endpoint designs leave unaddressed questions requires a level of systematic monitoring that most research organisations lack the infrastructure to maintain.
Distinguishing crowded from genuinely addressed
A therapeutic area can have many trials without any of them actually resolving the key clinical questions. Identifying white-space requires going beyond trial counts – to understand what endpoints are being measured, what patient populations are excluded, and what research questions remain unanswered despite apparent activity.
Positioning new trials competitively
In oncology research funding, demonstrating that a proposed trial addresses an unmet need that existing work doesn't cover is a core requirement for grant success and industry sponsorship. Without intelligence on the competitive landscape, trial proposals are written in a vacuum – and often lose to proposals that demonstrate better situational awareness.
Systematic protocol analysis. Sub-segment mapping. White-space identification grounded in endpoint and population analysis.
Trial landscape mapping across 12 sub-segments
Systematically mapped the clinical trial landscape across 12 oncology sub-segments – covering active trials, recently completed trials (last 36 months), and trials with results available but endpoints not yet fully published. Each sub-segment was characterised by trial density, sponsor mix (industry vs. academic), phase distribution, and the primary endpoints being evaluated.
Protocol analysis & endpoint review
Analysed over 200 trial protocols in detail – reviewing inclusion/exclusion criteria, primary and secondary endpoints, patient population definitions, treatment arm designs, and biomarker strategies. This analysis identified the specific research questions that remained unanswered across the landscape and the patient sub-populations systematically excluded from existing trials.
White-space identification
Synthesised the protocol analysis into a structured white-space assessment – identifying three specific research opportunities where existing trial activity was insufficient to resolve key clinical questions, where the target patient population had high unmet need, and where the organisation's existing capabilities and infrastructure created a credible advantage over potential competitors for the same space.
Trial research briefs
Produced detailed research briefs for two of the three white-space opportunities – including the clinical rationale, landscape positioning (demonstrating what existing trials don't cover), suggested trial design elements, target patient population definition, and key competitive differentiation arguments for funding applications and industry sponsorship conversations.
"The oncology clinical trial landscape is enormous. GreyRadius gave us the structured intelligence to identify where the real white-space was – not just what was already crowded."
12 sub-segments mapped. 200+ protocols analysed. 3 white-spaces identified. 2 trial briefs delivered.
Coverage
12 sub-segments
Full landscape characterisation by phase, sponsor type, endpoint design, and trial density
Analysis
200+ protocols
Full protocol review including inclusion/exclusion criteria, endpoints, populations, and biomarker strategy
Opportunities
3 white-spaces
Specific opportunities where unmet need is high and existing trial activity leaves key questions unanswered
Deliverables
2 trial briefs
Funding-ready briefs with clinical rationale, landscape positioning, and design recommendations
12-sub-segment oncology trial landscape analysis with trial density maps, phase distribution, sponsor profiles, and endpoint trend analysis.
Three specific research opportunities characterised by clinical rationale, patient population unmet need, and competitive positioning relative to existing trials.
Structured database of 200+ analysed protocols with standardised fields enabling ongoing monitoring as new trials are registered.
Two funding-ready briefs – with clinical rationale, landscape competitive positioning, suggested design, and arguments for grant and industry sponsorship applications.
The protocol analysis GreyRadius delivered went far beyond a literature review. They identified three specific white-space opportunities that have since become the basis of our new trial planning cycle.
"In oncology research, the difference between a funded trial and an unfunded one often comes down to competitive positioning – demonstrating that your study addresses an unmet need that existing trials don't cover. Intelligence that maps the trial landscape is a strategic asset, not a literature exercise."
Planning a clinical trial programme or research investment strategy?
We bring structured market intelligence to healthcare research strategy – landscape analysis, white-space identification, and funding-ready positioning for oncology, cardiology, and rare disease programmes.